Christian Junghanss

TL;DR: The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) as mentioned in this paper.

TL;DR: The results show a heterogeneous and inversely correlated expression profile of TRP-metabolizing genes among GBM and HNSCC cells, with low, but inducible IDO1 expression upon IFNγ treatment, and imply inhibition of the TRP catabolism by Dinaciclib, while conventional chemotherapeutics tend to activate this pathway.

TL;DR: It is demonstrated that loss of PF occurs during the first month followed by a regain during the subsequent 2 months in the absence of aGVHD, and the HAP and the grip test may serve as surrogate marker for the strength loss in the course of aGFD.

TL;DR: The data showed that higher dose or prolonged therapy did not result in increased rate of adverse events, and the preliminary experience with the use of LMV for the treatment of patients with refractory CMV infection/disease was positive.

TL;DR: Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment.